<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02983071</url>
  </required_header>
  <id_info>
    <org_study_id>G1T38-02</org_study_id>
    <secondary_id>2016-001485-29</secondary_id>
    <nct_id>NCT02983071</nct_id>
  </id_info>
  <brief_title>G1T38, a CDK 4/6 Inhibitor, in Combination With Fulvestrant in Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer</brief_title>
  <official_title>Phase 1/2 Safety, Pharmacokinetic, and Antitumor Activity Study of G1T38 in Combination With Fulvestrant in Patients With Hormone Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer After Endocrine Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the potential clinical benefit of G1T38 as an oral therapy in
      combination with fulvestrant in patients with hormone receptor-positive, HER2-negative
      metastatic breast cancer.

      The study is an open-label design, consists of 2 parts: dose-finding portion (Part 1), and
      expansion portion (Part 2). Both parts include 3 study phases: Screening Phase, Treatment
      Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day of first dose with
      study treatment and completes at the Post-Treatment Visit. Approximately, 102 patients will
      be enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2017</start_date>
  <completion_date type="Anticipated">December 2020</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Week 1 Day 1-Week 5 Day 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose</measure>
    <time_frame>14 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 dose interval</measure>
    <time_frame>14 months</time_frame>
    <description>Twice-Daily or Once-Daily dosing</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Treatment Related Adverse Event, including Abnormal Laboratory Events</measure>
    <time_frame>36 months</time_frame>
    <description>All AEs, including clinical laboratory, vitals signs, physical examinations and ECGs will be analyzed in all patients receiving study drug from the signing of the informed consent until 30 days after the last dose of study medication up to 36 months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tumor response based on RECIST, Version 1.1</measure>
    <time_frame>30 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Week 1 Day 1-Week 9 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Area under Curve - plasma concentration (AUC)</measure>
    <time_frame>Week 1 Day 1-Week 9 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Plasma: terminal half life (T1/2)</measure>
    <time_frame>Week 1 Day 1-Week 9 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of G1T38, Fulvestrant, and Goserelin: Plasma - Volume of distribution</measure>
    <time_frame>Week 1 Day 1-Week 9 Day 1</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>48 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">102</enrollment>
  <condition>Carcinoma, Ductal, Breast</condition>
  <condition>Breast Cancer</condition>
  <condition>Breast Neoplasm</condition>
  <arm_group>
    <arm_group_label>Once-Daily G1T38 Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 orally (once daily) in combination with fulvestrant.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Twice-Daily G1T38 Dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>G1T38 orally (twice daily) in combination with fulvestrant.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G1T38</intervention_name>
    <arm_group_label>Once-Daily G1T38 Dosing</arm_group_label>
    <arm_group_label>Twice-Daily G1T38 Dosing</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fulvestrant</intervention_name>
    <arm_group_label>Once-Daily G1T38 Dosing</arm_group_label>
    <arm_group_label>Twice-Daily G1T38 Dosing</arm_group_label>
    <other_name>Faslodex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Confirmed diagnosis of HR-positive, HER2-negative breast cancer, not amenable to
             curative therapy

          -  Pre- or perimenopausal women can be enrolled if amenable to be treated with goserelin

          -  Patients must satisfy 1 of the following criteria for prior therapy:

               -  Progressed during treatment or within 12 months of completion of adjuvant therapy
                  with an aromatase inhibitor or tamoxifen

               -  Progressed during treatment or within 2 months after the end of prior aromatase
                  inhibitor therapy for advanced/metastatic breast cancer, or prior endocrine
                  therapy for advanced/metastatic breast cancer

               -  Received ≤ 2 chemotherapy regimens (Part 1) or ≤ 1 chemotherapy regimen (Part 2)
                  for advanced/metastatic disease

          -  For Part 1, evaluable or measurable disease (bone only disease eligible for Part 1
             only)

          -  For Part 2, measurable disease as defined by RECIST, Version 1.1

          -  ECOG performance status 0 to 1

          -  Adequate organ function

        Exclusion Criteria:

          -  For Part 1, prior treatment with fulvestrant

          -  For Part 2, prior treatment with any CDK inhibitor or fulvestrant

          -  Active uncontrolled/symptomatic CNS metastases, carcinomatous meningitis, or
             leptomeningeal disease

          -  Chemotherapy within 21 days of first G1T38 dose

          -  Investigational drug within 28 days of first G1T38 dose

          -  Concurrent radiotherapy, radiotherapy within 14 days of first G1T38 dose, previous
             radiotherapy to the target lesion sites, or prior radiotherapy to &gt; 25% of bone marrow

          -  Prior hematopoietic stem cell or bone marrow transplantation
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1Therapeutics Clinical Contact</last_name>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Infekcni oddeleni, Fakultni nemocnice v Motole</name>
      <address>
        <city>Gabrovo</city>
        <zip>5300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Blaga Baeva-Rabotilova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHAT for Womens Health - Nadezhda OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1330</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Margarita Taushanova, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comac Medical</name>
      <address>
        <city>Sofia</city>
        <zip>1618</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marchela Koleva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Special Hospital For Active Treatment In Oncology</name>
      <address>
        <city>Sofia</city>
        <zip>1756</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Galina Kurteva, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ARENSIA Exploratory Medicine LLC</name>
      <address>
        <city>Tbilisi</city>
        <zip>0112</zip>
        <country>Georgia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Marina Maglakelidze, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Institute of Oncology</name>
      <address>
        <city>Chisinau</city>
        <zip>2025</zip>
        <country>Moldova, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Iurie Bulat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Richard Baird, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University College London Hospital (UCLH)</name>
      <address>
        <city>London</city>
        <zip>NW1 2BU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Rebecca Roylance, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Hendrik-Tobias Arkenau, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Wardley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Georgia</country>
    <country>Moldova, Republic of</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Czechia</country>
    <country>Romania</country>
  </removed_countries>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2016</study_first_submitted>
  <study_first_submitted_qc>December 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2016</study_first_posted>
  <last_update_submitted>February 13, 2018</last_update_submitted>
  <last_update_submitted_qc>February 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>CDK 4/6 Inhibitor</keyword>
  <keyword>HER2-Negative</keyword>
  <keyword>HR-Positive</keyword>
  <keyword>HR+</keyword>
  <keyword>HER2-</keyword>
  <keyword>HER2 -ve</keyword>
  <keyword>HER2 +ve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hormones</mesh_term>
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Fulvestrant</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

